Status of programmed death-1/programmed death-ligand 1 inhibitors in combination with vascular endothelial growth factor/vascular endothelial growth factor receptor inhibitors in advanced refractory colorectal cancer
Objective To analyze the status of applying programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors combined with vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR)inhibitors in advanced refractory colorectal cancer.Method The relevant literature on domestic and foreign research in recent years was summarized.Results The discovery of immune checkpoint PD-1/PD-L1 and the clinical application of related drugs had changed the treatment pattern of advanced solid tumors,but PD-1/PD-L1 inhibitors had a poor efficacy in the mismatch repair prodicient tumors,and most advanced colorectal cancer belonged to this type.The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors could enhance the therapeutic effect in the advanced refractory colorectal cancer,and their interaction mechanisms and clinical efficacy were continuously being proven.Conclusions The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors is a promising treatment strategy for advanced refractory colorectal cancer.More studies need to be further clarified its efficacy.
NETL
NSTL
万方数据
